ANI Pharmaceuticals price target raised to $65 from $62 at Truist

Truist analyst Les Sulewski raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $65 from $62 and keeps a Hold rating on the shares as part of a broader research note previewing Q1 results in BioPharma. The company’s generics U.S. manufacturing footprint is a plus as tariffs will likely take center stage in line of questioning, as will Medicare negotiation impacts and commentary around FDA staff cuts, the analyst tells investors in a research note.